Tricyclic Compounds Targeting Alpha-7 Nicotinic Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for schizophrenia and Alzheimer's disease have limitations in addressing negative symptoms, cognitive deficits, and side effects, while also failing to effectively improve cognitive function and delay institutionalization in Alzheimer's patients.
Innovation Solution
Development of compounds that act as α7 nicotinic receptor agonists and partial agonists, which can be used to treat various disorders of the central nervous system, including schizophrenia and Alzheimer's disease, by improving cognitive function and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic agents are used to treat schizophrenia, then positive symptoms are reduced, but negative symptoms and cognitive deficits remain untreated
Solution Approach 1:
The patent changes the pharmacological parameter from D2 dopamine receptor antagonism to α7 nicotinic acetylcholine receptor agonism. This parameter change enables the compound to address negative symptoms and cognitive deficits while maintaining efficacy against positive symptoms, thus resolving the contradiction between reliability for positive symptoms and adaptability for negative symptoms and cognitive deficits
2Reliability
If current antipsychotic agents are used, then positive symptoms are reduced, but unwanted side effects occur
Solution Approach 1:
The patent changes the receptor target parameter from D2 dopamine receptors to α7 nicotinic acetylcholine receptors. This parameter change allows the compound to reduce positive symptoms through a different mechanism that avoids the side effects associated with D2 antagonism, such as extrapyramidal symptoms and metabolic disturbances
Solution Approach 2:
The patent introduces α7 nicotinic acetylcholine receptors as an intermediary mechanism. These receptors serve as a mediator that can reduce positive symptoms through cholinergic pathways without triggering the harmful side effects associated with direct dopamine antagonism, thus resolving the contradiction between symptom reduction and side effect profile
3Reliability
If Alzheimer's disease patients are not treated effectively, then cognitive function deteriorates, but institutionalization occurs earlier
Solution Approach 1:
The patent changes the therapeutic parameter from conventional Alzheimer's treatments to selective α7 nicotinic acetylcholine receptor agonism. This parameter change targets the specific cholinergic deficit in Alzheimer's disease, improving cognitive function maintenance and potentially delaying institutionalization by addressing the underlying cholinergic impairment
Data Source
AI summary
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.